Levovir likely to remarketed this week

The Food and Drug Administration will announce a plan to allow the re-sales of Levovir (clevudine) sooner or later, as the Central Pharmaceutical Affairs Review Committee made a final conclusion on May 7 that its risk benefit ratio is sufficient to do so.

Levovir is the 11th Korean new drug developed by Bukwang Pharm during the past 12 years. Levovir is also the 4th compound ever developed i...